Organigram Global (STU:0OG) PE Ratio without NRI: 6.94 (As of Aug. 13, 2026) — 77% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0OG Organigram Global Inc STU:0OG
64 GF Score
Price €1.08
GF Value €1.58
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Organigram Global PE Ratio without NRI?

Organigram Global STU:0OG +3.44% 64 PE Ratio without NRI is 6.94 as of Aug. 13, 2026, which is 77% below its 10-year median of 30.80. GuruFocus rates STU:0OG with a GF Score™ of 64/100 and a GF Value™ of €1.58 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 649 Drug Manufacturers companies, Organigram Global ranks worse than 154083.05% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-08-13), Organigram Global's share price is €1.082. Organigram Global's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was €0.16. Therefore, Organigram Global's PE Ratio without NRI for today is 6.94.

During the past 13 years, Organigram Global's highest PE Ratio without NRI was 23720.00. The lowest was 0.00. And the median was 30.80.

Organigram Global's EPS without NRI for the three months ended in Jun. 2026 was €0.21. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was €0.16.

As of today (2026-08-13), Organigram Global's share price is €1.082. Organigram Global's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.38. Therefore, Organigram Global's PE Ratio (TTM) for today is 2.85.

During the past years, Organigram Global's highest PE Ratio (TTM) was 393.33. The lowest was 0.00. And the median was 32.00.

Organigram Global's EPS (Diluted) for the three months ended in Jun. 2026 was €0.48. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.38.

Organigram Global's EPS (Basic) for the three months ended in Jun. 2026 was €0.48. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.39.


Organigram Global  (STU:0OG) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Organigram Global PE Ratio without NRI Related Terms


Organigram Global PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Organigram Global's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organigram Global PE Ratio without NRI Chart

Organigram Global Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Sep24 Sep25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Organigram Global Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss 135.88 At Loss At Loss

STU:0OG vs ZTS: PE Ratio without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organigram Global PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organigram Global's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Organigram Global's PE Ratio without NRI falls into.


STU:0OG
64GF Score
Organigram Global Inc STU:0OG
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organigram Global PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Organigram Global's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=1.082/0.156
=6.94

Organigram Global's Share Price of today is €1.082.
Organigram Global's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.16.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 6.94 mean?
Organigram Global (STU:0OG) has a PE Ratio without NRI of 6.94 as of Aug. 13, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Organigram Global and its competitors. This is 77% below median its historical median of 30.80. According to the industry distribution chart, Organigram Global ranks #999999 out of 649 companies in the Drug Manufacturers industry.
Is Organigram Global's PE Ratio without NRI too high?
Organigram Global's current PE Ratio without NRI of 6.94 is 77% below median its 10-year median of 30.80. The Drug Manufacturers industry median PE Ratio without NRI is 20.89. Organigram Global's value of 6.94 is 66.8% below this industry median. Based on the distribution chart, Organigram Global ranks #999999 out of 649 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Organigram Global has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's PE Ratio without NRI compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #999999 out of 649 companies for PE Ratio without NRI. This places Organigram Global in the lower half of its industry. The industry median PE Ratio without NRI is 20.89. Organigram Global's value of 6.94 is 66.8% below this benchmark. While the company's 10-year median is 30.80 vs. the industry median of 20.89, Organigram Global has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.89, based on 649 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current PE Ratio without NRI of 6.94 is 66.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current PE Ratio without NRI is 6.94, which is 77% below median its own 10-year median of 30.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.58, compared to a current price of €1.08 — trading 31.5% below its estimated fair value. The current PE Ratio without NRI is 6.94, which is 77% below median its 10-year median of 30.80 and 66.8% below the Drug Manufacturers industry median of 20.89. Organigram Global's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current PE Ratio without NRI is 6.94 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organigram Global (STU:0OG) Overvalued in 2026?

Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued. The current stock price of €1.08 is trading 31.5% below its estimated GF Value™ of €1.58. GuruFocus considers Organigram Global to be Possible Value Trap.

Key valuation signals for STU:0OG:

  • PE Ratio without NRI: 6.94 (77% below median its 10-year median of 30.80)
  • GF Value™: €1.58 vs. price of €1.08 (31.5% below fair value)
  • GF Score™: 64/100 with 1 warning sign
  • Industry Position: 66.8% below the Drug Manufacturers median (#999999 of 649)

No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organigram Global Business Description

Other Exchanges OGI:USAOGI:Canada
Address 145 King Street West, Suite 1400, Toronto, ON, CAN, M5H 1J8
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
64GF Score

Get the complete analysis for STU:0OG

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.08
Price
€1.58
GF Value